Bertilimumab is under clinical development by Satellos Bioscience and currently in Phase II for Vernal Keratoconjunctivitis. According to GlobalData, Phase II drugs for Vernal Keratoconjunctivitis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bertilimumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bertilimumab overview
Bertilimumab (Ico-008, CAT-213) is under development for the treatment of vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis, allergic conjunctivitis and bullous pemphigoid. The drug candidate is administered intravenously. The drug candidate is a human immunoglobulin monoclonal antibody targeting eotaxin-1. It was also under development for the treatment of primary sclerosing cholangitis (PSC), allergic rhinitis, Crohn's disease, psoriasis, ulcerative colitis, non-alcoholic steatohepatitis (NASH), acute asthma and atopic dermatitis.
It was under development for the treatment of inflammatory diseases.
Satellos Bioscience overview
Satellos Bioscience (Satellos) is a biotech company which offers various solution such as muscular dystrophies, ageing muscle and muscle-wasting disorders. The company develops novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program focuses on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, Satellos has identified as a root cause of the progressive nature of this disease. The company operating under the brands MyoReGenX and Oral-Trans. The company offers various partnership arrangements with other drug developers and universities. Satellos is headquartered in Ontario, Canada.
For a complete picture of Bertilimumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
